New Haven, CT, Nov 6, 2024 – Cogstate, a leading neuroscience technology company, today announced the appointment Dr. Annamarie Vogt, PhD, as Associate Vice President, Alzheimer’s Disease (AD) Study Design and Endpoint Quality. Dr. Vogt brings to the role her extensive expertise in neuropsychological assessments, clinical endpoints, and nearly two decades of drug development experience in the pharmaceutical industry.
Dr. Vogt will direct and oversee the development of strategies, products, and services related to delivery of global AD and related clinical trials. Using her wide-ranging knowledge of neurodegenerative disease and biopharmaceutical programs, Dr. Vogt will help Cogstate deliver the highest standards in endpoint selection and data quality assurance strategies. Additionally, Dr. Vogt will drive ongoing publication of Cogstate’s Alzheimer’s research, further strengthening the company’s position as industry leaders.
“We are thrilled to welcome Dr. Vogt to our team,” said Pam Ventola, PhD, Chief Science Officer. “Her deep knowledge of AD study design, coupled with her extensive experience in neuropsychology, will be invaluable as we continue to expand our capabilities and enhance our services to better support Alzheimer’s research globally.”
Before joining Cogstate, Dr. Vogt held positions at Roche Pharmaceuticals as Senior Principal Scientist, Clinical Expert Team Lead, Clinical Science Franchise Lead, in Neuroscience Research and Early Development. Prior to that, she held scientific positions at Novartis Neuroscience. Her experience spans work in key therapeutic areas such as Alzheimer’s disease, Parkinson’s disease, and Fragile X syndrome.
“Cogstate’s work in advancing Alzheimer’s disease research through technological innovations and thoughtful science has always impressed me,” said Dr. Vogt. “I now look forward to contributing to this team of exceptional neuroscientists as we collectively support meaningful study and endpoint enhancements for biopharmaceutical teams in their efforts to improve circumstances for patients, families, and communities.”
Dr. Vogt holds an MSc in Psychology and a PhD in Cognition and Brain Sciences from the University of Basel. She was also a lecturer on empirical research, biopsychology, memory and attention and a rater reviewer, assessing outcome measures in clinical trials. Prior to studying psychology, she obtained a degree in social education and was working with children and adolescents with mental disorders.
###
